Eurazeo acquired a majority stake in Sevetys from Ardian, which had previously financed the group's initial rapid expansion. The transaction included a EUR250 million equity injection from Eurazeo to fuel a new phase of aggressive growth. The investment thesis focuses on consolidating the highly fragmented French veterinary market, which is protected by specific regulatory barriers regarding clinical governance and independence. Sevetys positions itself as a sovereign French alternative to global giants like IVC Evidensia and AniCura. Under Eurazeo's ownership, the group successfully completed approximately 100 acquisitions in 2022 alone, expanding its footprint into new regions such as the Rhone Valley and Grenoble.

The transaction values SEVETYS at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.